All In Biotech

Drug Trial Radar · NCT07254806

A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease

A Prospective, Randomized, Double-Blinded, Sham-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of IDCT in Subjects With Single-Level, Symptomatic Mild to Moderate Lumbar Intervertebral Disc Degeneration

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 162 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

162

Planned (sponsor's estimate)

Start

Dec 23, 2025

Primary completion

Nov 24, 2027

Study completion Nov 24, 2028

Sponsor

Lead sponsor
DiscGenics, Inc.Industry
Sponsor type
Industry
First posted
Nov 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, randomized, double-blinded, Sham-controlled, multi-center study in subjects with single-level, symptomatic lumbar (L3- S1) intervertebral disc degeneration. The study will have a 52-week primary period followed by 52 week Follow-up Period (total of 104 weeks). The study protocol will be approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC), and the study will be conducted in accordance with Good Clinical Practice (GCP). All subjects will provide written informed consent prior to Screening. Approximately 162 subjects will be enrolled in the study. Up to 45 days prior to treatment, subjects will be screened for study inclusion, which includes obtaining baseline MRI and X-ray imaging. Imaging results for subjects initially eligible for study participation will be sent to a central imaging vendor for review and confirmation of eligibility, including the number of levels with degeneration. Subjects meeting all inclusion/exclusion criteria will be assigned to the corresponding treatment arm group and subsequently randomized to IDCT or Sham. Randomization will occur approximately 7 to 14 days prior to the scheduled treatment administration date. Overall, 162 subjects will be enrolled and randomized to IDCT or Sham in a 2:1 ratio. * IDCT (n=108) * Sham (n=54)

Conditions

  • Degenerative Disc Disease

Interventions

  • IDCT (rebonuputemcel)Biological

    Single intradiscal injection of 1 mL of 9,000,000 cells/mL IDCT in a single target disc.

  • Sham (No Treatment)Other

    Single Sham needle insertion up to the annulus of a single target disc.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visual Analogue Scale (VAS) for low back painTime frame: Week 52
  2. Oswestry Disability Index (ODI)Time frame: Week 52
  3. Adverse EventsTime frame: Day 1 to Week 52 in each treatment group.
  4. Adverse events of special interestTime frame: Day 1 to Week 52 in each treatment group

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Alabama Clinical Therapeutics

    Birmingham, Alabama · Recruiting

  • Mayo Clinic (AZ)

    Phoenix, Arizona · Recruiting

  • HonorHealth

    Scottsdale, Arizona · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Solaris Research Institute

    San Diego, California · Recruiting

  • Source Healthcare

    Santa Monica, California · Recruiting

  • Pain Management and Injury Relief

    Thousand Oaks, California · Recruiting

  • International Spine, Pain and Performance Center

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic (FL)

    Jacksonville, Florida · Recruiting

  • University of Miami Health System

    Miami, Florida · Recruiting

  • Conquest Research

    Orlando, Florida · Recruiting

  • Vantage Clinical Trials

    St. Petersburg, Florida · Recruiting

  • Vantage Clinical Trials

    Tampa, Florida · Recruiting

  • Injury Care Family Care Research

    Boise, Idaho · Terminated

  • Axis Spine Center

    Post Falls, Idaho · Recruiting

  • Rush University Medical Center

    Chicago, Illinois · Recruiting

  • Indiana Spine Group

    Carmel, Indiana · Recruiting

  • Norton Leatherman Spine Center

    Louisville, Kentucky · Recruiting

  • Ochsner Health System

    New Orleans, Louisiana · Recruiting

  • Mayo Clinic (MN)

    Rochester, Minnesota · Recruiting

  • The Orthopedic Center of St. Louis

    St Louis, Missouri · Recruiting

  • Weill Cornell Medicine for Comprehensive Spine Care

    New York, New York · Recruiting

  • Wake Research

    Wilmington, North Carolina · Recruiting

  • Carolinas Pain Institute/ Center For Clinical Research

    Winston-Salem, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Pacific Sports and Spine

    Eugene, Oregon · Recruiting

  • Main Line Spine

    King of Prussia, Pennsylvania · Recruiting

  • Semmes Murphey Neurological Clinic

    Memphis, Tennessee · Recruiting

  • Pain Specialists of America

    Austin, Texas · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • Virginia iSpine Physicians

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.